What is the recommended acute management for a patient with decompensated liver failure?

Acute Management of Decompensated Liver Failure

In patients with decompensated liver failure, immediately initiate systematic N-acetylcysteine regardless of etiology, establish early contact with a transplant center, identify and treat precipitating factors, and provide aggressive organ support while rapidly determining transplant candidacy. 1

Initial Assessment and Stabilization

Immediate Diagnostic Workup

Upon presentation with decompensated liver failure, obtain the following critical investigations 1:

Laboratory studies:

• Acetaminophen serum level (even without clear history)
• Hepatitis serology: IgM VHA, HBsAg, anti-HBc IgM
• Prothrombin time/INR and Factor V
• Arterial blood gas with lactate
• Arterial ammonia level
• Blood glucose (monitor at least every 2 hours)
• Serum sodium (target 140-145 mmol/L)
• Phosphate, magnesium, potassium

Imaging:

• Hepatic Doppler ultrasound
• Echocardiography
• Urine toxicology screen (amphetamine, cocaine)

Universal Treatment Measures

Administer N-acetylcysteine systematically regardless of suspected etiology - this represents a paradigm shift from older acetaminophen-only protocols 1. Contact the transplant center immediately upon diagnosis, as early involvement improves outcomes even if transplantation is not ultimately performed.

Hemodynamic Management

Fluid Resuscitation

Careful attention to intravascular volume is critical 2:

• Use balanced (normochloremic) crystalloid solutions over normal saline for fluid replacement 3
• Consider pulmonary artery catheterization in hemodynamically unstable patients to ensure adequate volume replacement 2
• Assess volume status, cardiac output, and biventricular function 1

Vasopressor Support

If fluid replacement fails to maintain mean arterial pressure of 50-60 mm Hg 2:

• Use norepinephrine, epinephrine, or dopamine (not vasopressin, which is potentially harmful in acute liver failure) 2
• Norepinephrine is generally preferred as first-line agent

Neurologic Management

Hepatic Encephalopathy Grading and Intervention

Grade I-II encephalopathy:

• Monitor frequently in quiet environment
• Transfer to ICU if consciousness declines
• Avoid sedatives, benzodiazepines, and psychotropic drugs 1
• Do NOT use lactulose or rifaximin in acute liver failure - these are contraindicated 1

Grade III-IV encephalopathy (Glasgow <8):

• Intubate for airway protection 1
• Position head elevated at 30 degrees 2
• Use propofol for sedation in minimal doses (long half-life in liver failure)
• Use endotracheal lidocaine before suctioning to minimize ICP spikes 2

Intracranial Hypertension Management

• Suggest hypertonic saline for patients at risk of intracranial hypertension 3
• Suggest plasma exchange when available for hyperammonemia in acute liver failure 3
• Do NOT routinely use invasive ICP monitoring in advanced-grade encephalopathy 3
• Do NOT routinely use induced moderate hypothermia (<34°C) 3
• Maintain serum sodium 140-145 mmol/L 1

Renal Management

If dialysis is needed:

• Use continuous renal replacement therapy rather than intermittent hemodialysis 2
• Avoid nephrotoxic drugs including NSAIDs 1
• Treat hepatorenal syndrome-AKI according to specific protocols

Gastrointestinal Complications

Portal Hypertensive Bleeding

Strong recommendations 3:

• Perform esophagogastroduodenoscopy within 12 hours of presentation in critically ill ACLF patients with known or suspected portal hypertensive bleeding
• Use antibiotic prophylaxis for any type of upper GI bleeding
• Administer octreotide or somatostatin analog
• Use proton pump inhibitors
• Consider TIPS for recurrent variceal bleeding after failed medical/endoscopic intervention

Ascites Management

• Perform large volume paracentesis with intra-abdominal pressure measurement in patients with tense ascites and hemodynamic, renal, or respiratory compromise 3
• Do NOT perform paracentesis in patients with spontaneous bacterial peritonitis 3

Infection Management

Spontaneous Bacterial Peritonitis

Strong recommendations 3:

• Use broad-spectrum antibiotics for initial management
• Administer albumin (20% solution: 1.5 g/kg at diagnosis, 1 g/kg on day 3)
• Give appropriate antibiotics within 1 hour of shock onset if septic shock present

Prophylaxis

• Use systemic antifungal prophylaxis in liver transplant recipients with risk factors for invasive fungal infections 3
• Do NOT use selective bowel decontamination for critically ill liver transplant recipients 3

Coagulation Management

Critical principle: Do NOT routinely correct coagulation parameters 1, 2:

• Give vitamin K (at least one dose)
• Restrict clotting factors/FFP administration unless active bleeding or invasive procedures
• Consider platelets only for counts <10,000/mm³ or before invasive procedures
• Recombinant activated factor VII may be effective for invasive procedures 2

Metabolic and Nutritional Support

Glucose Management

• Manage hypoglycemia with continuous glucose infusions (symptoms obscured by encephalopathy) 2
• Monitor blood glucose at least every 2 hours 1

Electrolyte Management

Frequently supplement 2:

• Phosphate
• Magnesium
• Potassium

Nutrition

• Initiate enteral feedings early 2
• Provide 60 grams protein daily - do NOT severely restrict protein 2
• Branched-chain amino acids offer no superiority over standard enteral preparations
• Use parenteral nutrition only if enteral feeding contraindicated (increases fungal infection risk)

Respiratory Management

Apply standard lung-protective ventilator strategy according to ARDS protocols 1

Transplant Evaluation

Prognostic Indicators for Transplantation

King's College Criteria remain the gold standard 2:

For acetaminophen-induced ALF:

• Arterial pH <7.3 (after adequate volume resuscitation) regardless of coma grade, OR
• PT >100 seconds (INR >6.5) AND creatinine >3.4 mg/dL in Grade III/IV coma

For non-acetaminophen ALF:

• PT >100 seconds regardless of coma grade, OR
• Any 3 of: age <10 or >40 years, non-A/non-B hepatitis, drug-induced, jaundice >7 days before encephalopathy, PT >50 seconds, bilirubin >17.5 mg/dL

Poor prognostic etiologies suggesting need for transplant evaluation 2:

• Idiosyncratic drug injury
• Acute hepatitis B
• Autoimmune hepatitis
• Mushroom poisoning
• Wilson disease
• Budd-Chiari syndrome
• Indeterminate cause
• Coma grade III or IV on admission

Acute-on-Chronic Liver Failure (ACLF) Specific Considerations

For patients with underlying cirrhosis developing acute decompensation 4, 5:

ACLF is defined by:

1. Acute onset with rapid deterioration
2. Liver failure (elevated bilirubin AND elevated INR)
3. At least one extrahepatic organ failure (neurologic, circulatory, respiratory, or renal)

Management priorities:

• Rapid identification and reversal of precipitating factors (infection most common)
• Parallel organ support
• Repeated reassessment (clinical status can change rapidly)
• Urgent transplant evaluation when appropriate

Common Pitfalls to Avoid

1. Do NOT use lactulose, rifaximin, or ammonia-lowering treatments in acute liver failure - only indicated in ACLF with overt encephalopathy 3, 1
2. Do NOT routinely correct coagulation - reserve for active bleeding or procedures 1
3. Do NOT delay transplant center contact - early involvement improves outcomes regardless of transplant candidacy
4. Do NOT use vasopressin - potentially harmful in ALF 2
5. Do NOT restrict protein severely - provide adequate nutrition 2
6. Do NOT use intermittent hemodialysis - continuous modes preferred 2

What NOT to Do Summary 1

• Benzodiazepines or psychotropic drugs (e.g., metoclopramide)
• Lactulose or rifaximin in acute liver failure
• Nephrotoxic drugs including NSAIDs
• Routine correction of coagulation parameters

The management of decompensated liver failure requires simultaneous attention to multiple organ systems, early transplant evaluation, and avoidance of interventions that may worsen outcomes. The distinction between acute liver failure and acute-on-chronic liver failure guides specific therapeutic decisions, particularly regarding hepatic encephalopathy management.